Repros Therapeutics (RPRX) Tops Q3 EPS by 7c

Repros Therapeutics (NASDAQ: RPRX) reported Q3 EPS of ($0.32), $0.07 better than the analyst estimate of ($0.39).

For earnings history and earnings-related data on Repros Therapeutics (RPRX) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• Vireo Growth completes $20M Pennsylvania dispensary license deal
• Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.6% Yield